RANI · Rani Therapeutics Holdings, Inc. · Documents

Oct 20

Investor event

Chardan Healthcare Conference

Rani reported that RT-114 delivered PG-102 with bioavailability greater than 150% versus a matched subcutaneous dose in 30 healthy volunteers, without device-related adverse events; a 15-volunteer expansion precedes Phase 1B, with repeat-dose data expected in 2027.

Aug 13

Current report 8-K

Financial results AI summary on its way

Aug 13

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $1.71M Net loss $7.39M Diluted EPS -$0.04

Aug 12

Investor event

Canaccord Genuity 46th Annual Growth Conference AI summary on its way

Aug 4

Current report 8-K Events of Aug 1

Director or officer change, or executive pay AI summary on its way

Jun 30

Current report 8-K Events of Jun 24

Director or officer change, or executive pay AI summary on its way

May 29

Current report 8-K Events of May 28

Shareholder vote results AI summary on its way

May 27

Current report 8-K Events of May 26

Other events AI summary on its way

May 15

Current report 8-K Events of May 11

Financial results, Delisting notice or listing transfer, Director or officer change, or executive pay AI summary on its way

May 15

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Revenue $1.71M ▲ 893.0% Net loss $7.03M Diluted EPS -$0.04

Apr 16

Proxy statement DEF 14A Meeting May 28, 2026

Proxy statement AI summary on its way

Apr 16

Annual report to holders ARS

Annual report to holders AI summary on its way

Apr 16

Proxy statement DEFA14A

Proxy statement AI summary on its way

Mar 31

Investor event

Investor event AI summary on its way

Mar 26

Earnings call

Q4 2025 earnings call AI summary on its way

Mar 26

Current report 8-K

Financial results AI summary on its way

Mar 26

Annual report 10-K FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Revenue $1.63M ▲ 58.9% Net loss $29.67M Diluted EPS -$0.45

Jan 2

Current report 8-K Events of Dec 31

Ended a material agreement, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Shareholder vote results AI summary on its way

Nov 7

Registration statement S-3

Registration statement

Nov 6

Current report 8-K

Financial results

Nov 6

Quarterly report 10-Q FY2025 Q3, ended Sep 30

Quarterly report for FY2025 Q3

Revenue $0 Net loss $5.41M Diluted EPS -$0.12

Oct 27

Current report 8-K Events of Oct 22

Director or officer change, or executive pay, Other events

Oct 17

Current report 8-K Events of Oct 16

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Aug 8

Registration statement S-3

Registration statement

Aug 7

Current report 8-K

Financial results

Aug 7

Quarterly report 10-Q FY2025 Q2, ended Jun 30

Quarterly report for FY2025 Q2

Revenue $0 Net loss $6.69M Diluted EPS -$0.18

Jul 16

Current report 8-K Events of Jul 14

Other events

Jul 3

Registration statement S-3

Registration statement

Jun 26

Current report 8-K Events of Jun 20

Delisting notice or listing transfer

May 29

Current report 8-K Events of May 28

Shareholder vote results

May 20

Current report 8-K

Entered into a material agreement, Unregistered sale of equity

May 13

Current report 8-K

Financial results

May 13

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $172K Net loss $7.26M Diluted EPS -$0.22

May 6

Current report 8-K Events of May 1

Delisting notice or listing transfer

Apr 30

Current report 8-K Events of Apr 24

Director or officer change, or executive pay

Apr 30

Proxy statement DEFA14A

Proxy statement

Apr 16

Proxy statement DEF 14A Meeting May 28, 2025

Proxy statement

Apr 16

Annual report to holders ARS

Annual report to holders

Apr 16

Proxy statement DEFA14A

Proxy statement

Apr 9

Current report 8-K Events of Apr 7

Change of auditor

Mar 31

Current report 8-K

Financial results

Mar 31

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $1.03M Net loss $30.02M Diluted EPS -$1.05

Nov 14

Current report 8-K

Financial results

Nov 14

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Net loss $6.78M Diluted EPS -$0.24

Oct 16

Current report 8-K Events of Oct 15

Other events

Sep 11

Current report 8-K Events of Sep 10

Change of auditor

Aug 6

Current report 8-K

Current report

Aug 6

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Net loss $6.81M Diluted EPS -$0.26

Jul 23

Current report 8-K Events of Jul 22

Other events

Jul 12

Current report 8-K

Regulation FD disclosure